Cargando…

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas

The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjaanæs, Maria Moksnes, Halvorsen, Ann Rita, Solberg, Steinar, Jørgensen, Lars, Dragani, Tommaso A, Galvan, Antonella, Colombo, Francesca, Anderlini, Marco, Pastorino, Ugo, Kure, Elin, Børresen-Dale, Anne-Lise, Brustugun, Odd Terje, Helland, Åslaug
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Cancer Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235315/ https://www.ncbi.nlm.nih.gov/pubmed/24599520 http://dx.doi.org/10.1002/ijc.28828

Ejemplares similares

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2021)

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
por: Eide, Hanne A., et al.
Publicado: (2016)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
por: Nordgård, Oddmund, et al.
Publicado: (2013)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
por: Öjlert, Åsa Kristina, et al.
Publicado: (2019)

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
por: Nilssen, Yngvar, et al.
Publicado: (2023)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
por: Eide, Hanne Astrid, et al.
Publicado: (2016)

EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
por: Shao, Borong, et al.
Publicado: (2019)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
por: Berg, Janna, et al.
Publicado: (2021)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2012)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
por: Horndalsveen, Henrik, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor 3 (FGFR3)–Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas
por: Dai, Haiyan, et al.
Publicado: (2001)

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
por: Haakensen, Vilde Drageset, et al.
Publicado: (2021)

PathTracer: High-sensitivity detection of differential pathway activity in tumours
por: Nygård, Ståle, et al.
Publicado: (2019)

Profiling of microRNAs in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

Immune Cell Composition in Human Non-small Cell Lung Cancer
por: Stankovic, Branislava, et al.
Publicado: (2019)

Testing of human papillomavirus in lung cancer and non-tumor lung tissue
por: Galvan, Antonella, et al.
Publicado: (2012)

Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study
por: Bugge, Christoffer, et al.
Publicado: (2021)

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival
por: Helland, Å., et al.
Publicado: (2017)

Epigenome‐wide three‐way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early‐stage NSCLC
por: Ji, Xinyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_teos0o9pl17pkjo1bjes36pdsv